Abstract | OBJECTIVE: METHODS: Seven databases were searched from inception to September 21st, 2019. Randomized controlled trials comparing DHI combined with antihypertensive drugs versus antihypertensive drugs alone were extracted. The primary outcome was microalbuminuria (mALB). Secondary outcomes included systolic blood pressure (SBP), diastolic blood pressure (DBP), and serum creatinine (SCr). RESULTS: Fifteen studies were included in the meta-analysis, which indicated that DHI combined with antihypertensive drugs has advantages compared with antihypertensive drugs alone for reducing mALB [weighted mean difference (WMD) = -12.86, 95% confidence interval (CI) (-14.72, -11.0), P < 0.01], lowering SBP [WMD = -2.84, 95% CI (-4.56, -1.12), P = 0.001] and DBP [WMD = -2.38, 95% CI (-4.34, -0.43), P = 0.017], and decreasing SCr [WMD = -40.45, 95% CI (-55.69, -25.21), P < 0.01]. CONCLUSION:
|
Authors | YiZhuo Li, Shihai Yan, Lichao Qian, Lihua Wu, Yawei Zheng, Zhuyuan Fang |
Journal | Frontiers in pharmacology
(Front Pharmacol)
Vol. 11
Pg. 909
( 2020)
ISSN: 1663-9812 [Print] Switzerland |
PMID | 32636745
(Publication Type: Systematic Review)
|
Copyright | Copyright © 2020 Li, Yan, Qian, Wu, Zheng and Fang. |